siRNA-Mediated RNA Interference in Precision-Cut Tissue Slices Prepared from Mouse Lung and Kidney
Mitchel J R Ruigrok1, Nalinie Maggan1, Delphine Willaert1
1Groningen Research Institute of Pharmacy, Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands.
Abstract:
Small interfering RNA (siRNA)-mediated RNAi interference (RNAi) is a powerful post-transcriptional gene silencing mechanism which can be used to study the function of genes in vitro (cell cultures) and in vivo (animal models). However, there is a translational gap between these models. Hence, there is a need for novel experimental models that combine the advantages of in vitro and in vivo models (e.g., simplicity, flexibility, throughput, and representability) to study the effects of siRNA. This need may be addressed by precision-cut tissue slices (PCTS), which represent an ex vivo model that mimics the structural and functional characteristics of a whole organ. The goal of this study was to investigate whether self-deliverable siRNA (Accell siRNA) can be used in precision-cut lung slices (PCLuS) and precision-cut kidney slices (PCKS) to achieve RNAi ex vivo. PCLuS and PCKS were prepared from mouse tissue, and they were subsequently incubated up to 48 h with no siRNA (untransfected), non-targeting Accell siRNA, or Gapdh-targeting Accell siRNA. Significant Gapdh mRNA silencing was achieved (PCLuS ~ 55%; PCKS ~ 40%) without compromising the viability and morphology of slices. Fluorescence microscopy confirmed that Accell siRNA diffused into PCLuS and PCKS. Spontaneous inflammation upon incubation was observed in PCLuS and PCKS as shown by a higher mRNA expression of pro-inflammatory cytokines Il1b, Il6, and Tnfa, although Accell siRNA appeared to diminish this response in PCLuS after 24 h. In conclusion, this ex vivo transfection model can be used to evaluate the effects of siRNA in relevant biological environments.
Insights
Self-deliverable small interfering RNA (siRNA) effectively silences genes in precision-cut lung and kidney slices (PCLuS/PCKS) ex vivo. This model bridges the gap between cell cultures and animal studies for RNA interference research.
Area of Science:
- Molecular Biology
- Genetics
- Pharmacology
Background:
- RNA interference (RNAi) using small interfering RNA (siRNA) is crucial for gene function studies.
- Existing in vitro and in vivo models present translational challenges.
- A need exists for experimental models combining in vitro and in vivo advantages.
Purpose of the Study:
- To evaluate the efficacy of self-deliverable siRNA (Accell siRNA) in precision-cut lung slices (PCLuS) and precision-cut kidney slices (PCKS) for ex vivo RNAi.
- To assess the impact of Accell siRNA on slice viability and morphology.
- To investigate siRNA delivery and gene silencing in a relevant organoid model.
Main Methods:
- Preparation of precision-cut lung slices (PCLuS) and precision-cut kidney slices (PCKS) from mouse tissue.
- Incubation of slices with no siRNA, non-targeting Accell siRNA, or Gapdh-targeting Accell siRNA for up to 48 hours.
- Assessment of gene silencing via mRNA levels, cell viability, morphology, and siRNA diffusion using fluorescence microscopy.
Main Results:
- Significant Gapdh mRNA silencing was achieved in PCLuS (~55%) and PCKS (~40%) without compromising tissue integrity.
- Accell siRNA demonstrated diffusion into both PCLuS and PCKS.
- Spontaneous inflammation markers (Il1b, Il6, Tnfa) were observed, with Accell siRNA potentially mitigating this in PCLuS.
Conclusions:
- Precision-cut tissue slices (PCTS) provide a viable ex vivo model for siRNA-mediated RNAi.
- This model effectively mimics organ characteristics for studying siRNA effects.
- Accell siRNA is a promising tool for ex vivo gene silencing in lung and kidney tissues.
Related Concept Videos
Experimental RNAi
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...


